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Abstract
Background: ADAM8 (a disintegrin and metalloproteinase 8) protein promotes the invasive and metastatic
phenotype of triple-negative breast cancer (TNBC) cells. High ADAM8 expression in breast cancer patients is an
independent predictor of poor prognosis. Here, we investigated whether ADAM8 regulates specific miRNAs, their
roles in aggressive phenotype, and potential use as biomarkers of disease.
Methods: Microarray analysis was performed on RNA from MDA-MB-231 cells after transient ADAM8 knockdown
using TaqMan miRNA cards. Changes in miRNA levels were confirmed using two ADAM8 siRNAs in TNBC cell lines.
Kinase inhibitors, β1-integrin antagonist antibody, and different forms of ADAM8 were employed to elucidate the
signaling pathway required for miR-720 expression. miR-720 levels were modulated using a specific antagomiR or a
mimic, and effects on aggressive phenotype of TNBC cells were determined using Boyden chamber and 3D-
Matrigel outgrowth assays. Plasma was isolated from mice before and after implantation of MDA-MB-231 cells and
analyzed for miR-720 levels. Serum samples of TNBC patients were evaluated for their ADAM8 and miR-720 levels.
Results: We identified 68 miRNAs differentially regulated upon ADAM8 knockdown, including decreased levels of
secreted miR-720. Ectopic overexpression of wild-type ADAM8 or forms that lack metalloproteinase activity similarly
induced miR-720 levels. The disintegrin and cysteine-rich domains of ADAM8 were shown to induce miR-720 via
activation of a β1-integrin to ERK signaling cascade. Knockdown of miR-720 led to a significant decrease in
migratory and invasive abilities of TNBC cells. Conversely, miR-720 overexpression rescued these properties. A
profound increase in plasma levels of miR-720 was detected 7 days after TNBC cell inoculation into mouse
mammary fat pads when tumors were barely palpable. Concordantly, miR-720 levels were found to be significantly
higher in serum samples of TNBC patients with high ADAM8 expression.
Conclusions: We have shown for the first time that miR-720 is induced by ADAM8 signaling via ERK and plays an
essential role in promoting the aggressive phenotype of TNBCs. miR-720 is elevated in serum of patients with
ADAM8-high TNBC and, in a group with other miRNAs downstream of ADAM8, holds promise as a biomarker for
early detection of or treatment response of ADAM8-positive TNBCs.
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Background
Triple-negative breast cancers (TNBCs), which lack ex-
pression of the estrogen receptor alpha (ERα), progester-
one receptor, and human epidermal growth factor
receptor 2 (HER2), are particularly aggressive and clinic-
ally challenging to manage due to the absence of these
common therapeutic targets [1]. TNBC is responsible
for approximately 25 % of all breast cancer deaths, al-
though it represents only 15 % of patients diagnosed
with invasive breast cancer. TNBC patients have a
poorer clinical outcome, and experience a higher rate of
distant recurrence (34.0 % versus 20.4 % in other breast
cancers) [2]. In consequence, they have a lower 5-year
overall survival rate than patients with other breast can-
cer subtypes [3]. Younger women and women of
African-American descent are at a particularly high risk
of TNBC [4]. Therefore, there is a critical need to under-
stand the molecular mechanisms promoting the aggres-
sive phenotype of TNBCs and to identify additional
prognostic markers to improve early clinical diagnosis of
primary or recurrent disease [5].
MicroRNAs (miRNAs) are a class of endogenously
expressed, evolutionarily conserved, small noncoding
RNAs, which play crucial regulatory roles in a variety of
normal cellular processes [6]. Their aberrant expression
in cancer has been implicated in various signaling path-
ways affecting tumor initiation, growth, invasion, and
metastasis [7]. For example, miR-10b has been shown to
promote metastasis of 4T1 cell line-derived breast tu-
mors in a mouse mammary model [8]. In contrast, miR-
let-7 suppresses breast cancer cell migration and inva-
sion, in part through downregulation of C-C chemokine
receptor type 7 [9], while in lung cancer, low miR-let-7
levels lead to higher expression of RAS protein [10].
Blenkiron et al. showed that miR-155 is differentially
expressed in ERα– versus ERα + tumors, and is overex-
pressed in breast tumors compared to normal breast tis-
sue [11]. Differential expression of six miRNAs (miR-
142-3p, miR-505*, miR-1248, miR-181a-2*, miR-25* and
miR-340*) was found to accurately discriminate between
tumors from BRCA1/2 mutation carriers and noncar-
riers [12]. Furthermore, miRNAs are stable in both pri-
mary tumors and in the circulation, leading researchers
to propose their use as biomarkers for cancer diagnosis
and prognosis. The importance of circulating miRNAs
as biomarkers for breast cancer has been documented in
several studies [13–16]. For example, Zhu and coworkers
showed that miR-155 may be differentially expressed in
the serum of women with hormone-sensitive versus
hormone-insensitive breast cancer [15]. Madhavan et al.
demonstrated that breast cancer patients that are
positive for circulating tumor cells (CTCs) versus pa-
tients negative for CTCs had significantly higher
levels of miR-141, miR-200a, miR-200b, miR-200c,
miR-203, miR-210, miR-375, and miR-801 in their
plasma [13]. While considerable effort has been
invested in understanding how miRNAs regulate vari-
ous genes, much less is known about the regulation
of miRNA expression.
ADAM8 (a disintegrin and metalloproteinase 8) is a
transmembrane protein that belongs to the ADAM fam-
ily of proteins that mediate cell adhesion, cell migration,
and proteolysis of a variety of substrates in the extracel-
lular matrix [17]. ADAM8 is synthesized with a signal
sequence along with five domains, namely the prodo-
main (PRO), and the metalloproteinase (MP), disintegrin
(DI), cysteine-rich (CRD), and epidermal growth factor
(EGF)-like (ELD) domains. It also has a transmembrane
region and a cytoplasmic tail. The MP domain is catalyt-
ically active [18, 19] and can shed various cytokines and
their receptors. The DI and CRD domains of ADAM
proteins have been suggested to bind integrins and other
receptors, and mediate cell adhesion. This adhesion can
sometimes occur via an RGD sequence [20]; however,
ADAM8 lacks this sequence and Stone et al. [21] have
proposed that the three-dimensional (3D) structure of
the disintegrin loop, and not its sequence, may play an
important role in mediating these interactions. ADAM8
is synthesized as a 120-kDa proform, which can dimerize
or multimerize, and autocatalytically clip off its prodo-
main, leaving an active membrane-associated metallo-
protease of 90-kDa [22]. Active ADAM8 can be further
processed by the release of the MP domain into the extra-
cellular matrix, leaving behind a 60-kDa membrane-
associated remnant form. The cytoplasmic tail of ADAM8
is relatively long and has a conserved potential SH3 ligand
domain, similar to ADAM9 [23]. The natural ligands of
the ADAM8 cytoplasmic domain have not yet been identi-
fied, but it is likely that the tail has signaling potential.
Recently, our laboratory has shown that ADAM8 is
highly expressed in breast tumors, especially in TNBC,
compared to normal tissue and its level correlates with
poor patient outcome [24]. Furthermore, ADAM8 was
detected by immunohistochemistry in 48 % of all breast
cancer-derived metastases. Knockdown of ADAM8 in
TNBC cells decreased their ability to migrate, to invade
through Matrigel in a Boyden chamber assay, and to
form branched colonies in 3D-Matrigel outgrowth assays
in vitro. In an orthotopic mouse model, tumors derived
from human TNBC cells with ADAM8 knockdown
failed to grow beyond a palpable size due to impaired
angiogenesis, and showed greatly reduced ability to
metastasize [24]. Mechanistic studies identified two
major ADAM8 functions: (1) promoting angiogenesis
through release of VEGF-A and other pro-angiogenic
factors; and (2) activating β1-integrin on the cancer cells
needed for intravasation and extravasation allowing for
tumor dissemination and metastasis. Significantly,
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treatment with an anti-ADAM8 antibody targeting its
extracellular MP and DI domains reduced primary
tumor burden and metastases in mice [24]. Given the
key role ADAM8 plays in promoting invasion and me-
tastasis of TNBCs, here we tested the hypothesis that
ADAM8 mediates the aggressive phenotype of TNBC
cells through regulation of specific miRNAs. Using
ADAM8 knockdown strategies, 68 miRNAs were identi-
fied in MDA-MB-231 TNBC cells, including miR-720
which is overexpressed in several cancers [25] and se-
creted from TNBC cells. miR-720 was shown to be in-
duced by ADAM8 via a β1-integrin to ERK signaling
cascade, and to mediate signals that promote the inva-
sive and migratory phenotype of TNBC cells in culture.
In an orthotopic mouse model, miR-720 was detectable
in the serum of mice bearing ADAM8-expressing tu-
mors. Importantly, miR-720 levels were elevated in
serum samples of TNBC patients with high ADAM8 ex-
pression. Overall, these studies suggest that miR-720
plays an essential role in the aggressive phenotype of
ADAM8-positive TNBCs and may serve in a group of
miRNAs as a biomarker for early detection of recurrence




The ADAM8 antibody (B4068) used for Western blot-
ting was purchased from LifeSpan Biosciences. Anti-
bodies against β-actin (AC-15) and β-tubulin (TUB 2.1),
and the ERK inhibitor FR180204 (SML0320) were ob-
tained from Sigma-Aldrich. The antibody to detect spe-
cific ERK 1/2 phosphorylated forms (pERK1/2) (9101)
was obtained from Cell Signaling Technology. The β1-
integrin antibody (552828) and its control isotype
matched IgG2A (SC3883) were purchased from BD Bio-
sciences and Santa Cruz Biotechnology, respectively.
The anti-ADAM8 antibody MAB10311 and its control
isotype-matched IgG1 (MAB002) were from R&D
Systems.
Cells and culture conditions
The MDA-MB-231 and Hs578T human TNBC cell lines
and the human umbilical vein endothelial cell (HUVEC)
line were purchased from the American Type Culture
Collection (ATCC) and maintained in media recom-
mended by ATCC. Stable clones of ADAM8 short hairpin
RNA (shRNA) (shA8-20) and control shRNA (shCtrl-3)
MDA-MB-231 cells expressing green fluorescent protein
were isolated as described previously [24], and kindly pro-
vided by Joerg Bartsch (Philipps University, Marburg,
Germany). The identity of the MDA-MB-231 cell line and
the shA8-20 and shCtrl-3 MDA-MB-231 clones was au-
thenticated using short tandem repeat analysis (Genetica
DNA Laboratories), which showed 100 % identity with the
MDA-MB-231 cell line of ATCC. The inflammatory
breast cancer cell line SUM-149 was kindly provided by
Stephen Ethier (University of Michigan Medical School,
Ann Arbor, MI, USA) and maintained as previously
described [26]. HEK-293 cells were kindly provided by
Nader Rahimi (Boston University School of Medicine,
Boston, MA, USA). All cell cultures were confirmed to
be free of mycoplasma contamination using polymerase
chain reaction (PCR) (VenorGeM Mycoplasma Detection
Kit, Sigma). To test for the effects of inhibiting ADAM8
activity, cells were treated either with siADAM8 (see
below) or with 20 μg/ml anti-ADAM8 antibody
MAB10311, or control isotype IgG1 MAB002. To test
for the effects of inhibition of β1-integrin signaling,
cells were treated with 10 or 20 μg/ml of either antag-
onist β1-integrin antibody or control isotype (IgG2A
rat). To inhibit ERK signaling, cells were treated with
25 μM FR180204.
Cloned DNA and plasmid transfection
The human full-length ADAM8 (hADAM8) cDNA
(MGC:134985; Genbank:BC115404.1) and the remnant
form ADAM8 cDNA were kindly provided by Joerg
Bartsch as described previously [27]. The enzymatically
inactive mutant of hADAM8 was prepared as described
previously [28]. For transient transfection of shA8-20
cells, cultures were incubated for 48 h in the presence
of 4 or 8 μg total DNA in six-well or P60 plates, re-
spectively, with Lipofectamine 2000 (Invitrogen) trans-
fection reagent. For transfection of HEK-293 cells, 1 or
2 μg of total DNA in Lipofectoamine 2000 was used, as
indicated. Empty pcDNA3 vector (EV) or pcDNA3.1
myc-his vector (EV-3.1) DNA were used as negative
controls.
siRNA knockdown analyses
Transient RNAi-mediated ADAM8 knockdown was






AllStar negative control siRNA (Qiagen) was used as a
non-silencing control siRNA (siCtrl). siRNAs (10 nM)
were introduced in MDA-MB-231 or SUM-149 cells
using Lipofectamine RNAi Max Transfection Reagent
(Invitrogen) by reverse transfection according to the
manufacturer’s protocol. Transfected cells were used 48
or 72 h later in functional assays.
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miRNA microarray analysis and validation studies
MDA-MB-231 cells were transiently transfected with
siADAM8-2 or siCtrl. Total RNA was isolated 72 h after
transfection using TRIzol reagent (Invitrogen), according
to the manufacturer’s protocol and quantified using a
Take3 plate reader (BioTek Synergy HT). We chose 72 h
post-transfection for functional assays to decrease effects
introduced as a result of the transfection protocol. RNA
integrity was assessed using the Agilent 2100 Bioanalyzer
(Agilent) and RNA 6000 Nano LabChip kit (5065–4476).
RNA with an RNA integrity number (RIN) >9.0 was
considered good quality. Array analysis was performed
using the TaqMan Array Human MicroRNA A + B cards
v3.0 (Life Technologies, 4444913) according to the man-
ufacturer’s protocol. Briefly, 1 μg total RNA was ampli-
fied and cDNA prepared using Megaplex Reverse
Transcriptase (RT) Human Pool Set v3.0 primers (Life
Technologies, 4444745) and TaqMan microRNA reverse
transcription kit (Invitrogen, 4366596). Subsequently,
6 μl of the cDNA preparation was diluted with TaqMan
Universal PCR Master Mix (450 μl) and nuclease free
water (444 μl) and loaded on the 384-well TaqMan
low-density array card. The cards were then centri-
fuged to distribute the cDNA samples in the reaction
wells using a refrigerated Sorvall and Heraeus bucket
centrifuge at 1200 rpm (331 × g) for two 1-min runs.
The plate was then sealed and the real-time PCR was
carried out on an Applied Biosystems 7900HT Real-
Time PCR system. The data were analyzed using SDS
software. Relative miRNA expression was calculated by
comparing MDA-MB-231 cells with ADAM8 knock-
down to cells with the control siRNA. This experiment
was performed in duplicate and miRNAs that showed
greater than twofold change in both replicates were se-
lected for study.
Mammary fat pad mouse model
All animal work was performed in accordance with a
protocol approved by the Institutional Animal Care and
Use Committee of Tufts University and Tufts Medical
Center. Blood was collected from 6-week-old female
nonobese diabetic/severe combined immunodeficient
(NOD/SCID) mice (Jackson Laboratory) using subman-
dibular bleeding and plasma isolated and processed as
described below. The next day, 2.5 × 106 shCtrl-3 MDA-
MB-231 cells in 40 μl 50 % Matrigel (BD Biosciences,
CB-40230A) solution (1:1 dilution of Matrigel with
DMEM medium) were implanted in the fourth inguinal
mammary fat pad. Primary tumor growth was monitored
by caliper measurement twice a week. Tumor volumes
were calculated as (length × width2)/2. At the indicated
times, blood was collected and processed as above. Mice
were sacrificed after 3–4 weeks when tumors derived
from shCtrl-3 cells had reached a volume of ~1 cm3.
Tumors were dissected, photographed, weighed and
flash frozen.
Quantitative RT PCR analysis of cell RNA
RNA was isolated from cells using TRIzol reagent and
DNA prepared using TaqMan MicroRNA Reverse Tran-
scription Kit (Invitrogen, 4366596) according to the
manufacturer’s protocol. Expression of miRNAs was
assessed by quantitative reverse transcription PCR (RT-
qPCR), using U6 snRNA (Invitrogen, 4427975) as the
control. Single tube TaqMan assays (Invitrogen,
4427975) were obtained for all miRNAs of interest (hsa-
miR-30d*, hsa-miR-181a-2*, hsa-miR-29c, rno-miR-
29C*, hsa-miR-93*, hsa-miR-520c-3p, hsa-miR-130b*,
hsa-miR-720, hsa-miR-106*b, hsa-miR-98, and hsa-miR-
20a*) and qPCR was carried out as follows: 95 °C for
10 min, then 40 cycles of 95 °C for 15 s and 60 °C for
60 s. All analyses were performed in triplicate and the
data were normalized to U6 snRNA. Average fold-
change ± SD in miRNA levels relative to those in control
untreated cells (set to 1) are presented.
RNA extraction from mouse plasma
Following isolation of mouse blood via submandibular
bleeding, 25 μl of a 10-mM EDTA solution was added to
individual samples to prevent coagulation. The samples
were stored on ice and centrifuged at 1300 g for 20 min
at 4 °C. Supernatants were collected and lysed as recom-
mended in the manufacturer’s protocol for the miRneasy
serum/plasma kit (Qiagen, 217184). Subsequently, 3.5 μl
of C. elegans miR-39 (Qiagen, 219610) (160 nM) was
added as a spike in each sample to control for miRNA
recovery. RNA was then isolated as per protocol. Re-
verse transcription was carried out using the miScript II
RT kit (Qiagen, 218161). miRNA expression was
assessed by qPCR, and values normalized to the control
C. elegans miR-39 (Ce_miR-39_1, MS00019789, Qiagen).
The miScript primer assay was used for qPCR of miR-
720 (Hs_miR720_1, MS00014833, Qiagen) as follows:
95 °C for 15 min, then 45 cycles of 94 °C for 15 s, 55 °C
for 30 s and 70 °C for 30 s. Average fold-change ± SD in
normalized miR-720 miRNA levels relative to those in
control untreated mice are presented.
Exosome isolation and RNA extraction
Exosome isolation was performed essentially as pub-
lished previously [29]. Briefly, cell lines were cultured in
ten P100 plates each until they reached 50–70 % con-
fluency. The culture media for MDA-MB-231, shA8-20
and shCtrl-3 cells were then replaced with serum-free
media, whereas, for SUM-149 cells which require serum
for their viability, exosome-depleted FBS media was
used. After 72 h, supernatants were collected, centri-
fuged at 2000 × g for 20 min to remove debris and
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filtered using a 0.22-μm filter. Exosomes were isolated
by ultracentrifugation at 100,000 × g for 70 min. The
exosome pellet was washed with PBS and RNA isolated
using the miRCURY RNA isolation kit-cell and plant
(Exiqon, 300110). Isolated RNA was subjected to Agilent
2100 Bioanalyzer (Agilent) analysis using a RNA 6000
Nano LabChip kit (5065–4476), which confirmed the
lack of rRNA in the miRNA samples. Levels of miR-720
expression, determined by RT-qPCR, are presented ±
SEM from two independent experiments.
miRNA knockdown and overexpression
MDA-MB-231 and SUM-149 cells were transfected in
six-well plates with 50 nM miR-720 mirVana miRNA in-
hibitor (Invitrogen, 4464084 (hsa_miR_720, assay id:
MH13574)) or negative-control (Invitrogen, 4464076) ol-
igonucleotides using Lipofectamine RNAi Max (Invitro-
gen). After 16 h, fresh media was added and the cells
were collected 48 h after transfection for functional ana-
lysis. To overexpress miR-720, ADAM8 knockdown
MDA-MB-231 cells (shA8-20 clone) were plated a day
prior to transfection. When cells reached 80 % con-
fluency, cultures were transfected overnight with 200
pmol miR-720-mimic (Invitrogen, 4464066 (assay id:
MC13574)) or the negative control mimic (Invitrogen,
4464058) using Lipofectamine 2000. The transfection
media were replaced with fresh media and cells har-
vested 48 h after transfection for functional analysis.
Western blot analysis
Whole-cell extracts (WCEs) were prepared using RIPA
buffer (50 mM Tris pH 7.6, 150 mM NaCl, 1 % NP-40,
0.1 % SDS, 5 mM EDTA, 1 % sodium sarkosyl) supple-
mented with protease and phosphatase inhibitors [30],
and 5 mM EDTA and 10 mM phenanthroline to inhibit
the autocatalytic activity of ADAM8. Lysates were soni-
cated and centrifuged at 16,000 g for 15 min. Protein
concentration in the supernatants was determined using
DC Protein Assay Reagent (BioRad). Samples (25 μg)
were subjected to immunoblotting as previously de-
scribed [27]. Either β-actin or β-tubulin was used as the
loading control.
ATP assay
As a measure of cellular metabolism and therefore cell
growth, ATP levels were assessed using an ATPlite lumi-
nescence ATP detection assay system (Perkin Elmer), as
described previously [31]. Briefly, cells (3000 cells/100 μl
for MDA-MB-231 and shA8-20, or 8000 cells/100 μl for
SUM-149) were plated in 96-well plates. After 24 h, an
equal volume of APTlite 1Step luminescence reagent
was added and luciferase activity measured. Average
ATP levels, for triplicate samples, are presented relative
to the control condition set to 1 (± SD).
Matrigel outgrowth, migration/invasion and
transendothelial migration assays
Matrigel outgrowth assays were carried out as described
previously [32], using 5 × 103 cells plated in duplicate in
24-well plates. Cultures were incubated for 11–15 days
and photographed at 10× magnification. Migration and
invasion assays were performed in triplicate using poly-
carbonate filter Transwells (Costar) with 8-μm diameter
pores, without precoating or precoated with growth
factor-reduced Matrigel (BD Biosciences, 356231), re-
spectively. For transendothelial migration, Transwells
were coated with a confluent layer of HUVECs instead
of Matrigel. Suspensions of 1 × 105 tumor cells were lay-
ered in the upper compartment of the Transwells and
incubated at 37 °C. After 24 h, cells that migrated or in-
vaded to the lower side of the filter were quantified by
crystal violet staining and OD570nm determination. The
negative control or control mimic condition was set to
100 % and the mean ± SD from three independent ex-
periments is given.
ELISA and RNA analysis of serum from TNBC patients
All clinical investigation was conducted in accordance
with the principles outlined in the Declaration of
Helsinki. Serum samples used in this work were pro-
vided by the Institut Régional du Cancer Nantes-
Atlantique tumor bank, funded by the Institut National
du Cancer (INCa) and approved by the French Minister
of higher education and research (n°. AC-2008-141). In-
formed consent was obtained from patients to use their
surgical specimens, serum, and clinicopathological data
for research purposes, as required by the French Com-
mittee for the Protection of Human Subjects (CCPPRB).
Ouest IV – Nantes CCPPRB approved use of serum
samples for this study (6 May 2013: n°. 357/2013). This
study did not need additional ethical approval.
Blood samples were collected in BD Vacutainer red-
top tubes (BD Biosciences, 367837) from 37 consenting
women diagnosed with TNBC in the Nantes Cancer
Center (ICO, France). At the time of sampling, patients
had not received any treatment in the form of surgery,
chemotherapy, radiation, or endocrine therapy. Blood
samples were allowed to clot for 1 h and centrifuged at
400 g for 10 min. Sera were stored at –80 °C within 2 h
of being taken. Detailed patient clinicopathological char-
acteristics are listed in Additional file 1 (Table S1). Sera
were also collected from 15 consenting healthy female
individuals. ADAM8 protein was measured in the serum
using an enzyme-linked immunosorbent assay (ELISA)
(R&D Systems) according to the manufacturer’s
instructions.
Serum samples from patients (150 μl) were thawed to
room temperature and processed as recommended for
the NucleoSpin miRNA plasma kit (Invitrogen, 740981).
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Fig. 1 Knockdown of ADAM8 alters miRNA expression in TNBC cells. a Schematic representation of the various domains of the human
ADAM8 protein and the different forms observed after processing in cancer cells. b, c MDA-MB-231 cells were transfected with
10 nM of either control siRNA (siCtrl) or the ADAM8 siRNAs siADAM8-1 or siADAM8-2 (siA8-1 or siA8-2). After 72 h, WCEs and RNA
were isolated. WCEs (25 μg) were examined by Western blotting for expression of ADAM8, and β-tubulin as a loading control. A
representative blot is shown (n = 3). ADAM8 forms and molecular weight (MW) markers are as indicated (b). RNAs isolated from siCtrl
and siADAM8-2 cells were subjected to an RT-qPCR-based miRNA array assay and the resulting heat map representation of miRNA
expression displaying a greater than twofold change presented as fold-changes in siADAM8-2 compared to siCtrl in two independent
experiments (Arrays 1 and 2) (c). The legend for the fold-changes in the heat map is given to the left. d RNA from MDA-MB-231 cells
transfected with 10 nM of siCtrl, siADAM8-1 or siADAM8-2 for 72 h were subjected to RT-qPCR for the indicated miRNAs. siCtrl was set
to 1 and the fold changes given as mean ± SD from three independent experiments. e WCEs from SUM-149 cells transfected with 10
nM of siCtrl, siADAM8-1 or siADAM8-2 for 72 h were subjected to Western blotting for expression of ADAM8, and β-actin as a loading
control. A representative blot is shown (n = 3). Positions of the proform, active and remnant forms of ADAM8 and MW markers are
as indicated. f RNAs were isolated from SUM-149 cells transfected, as in part e, and samples subjected to RT-qPCR for miR-720 levels.
siCtrl was set to 1 and relative (Rel.) levels of miR-720 are given (mean ± SD from three independent experiments). *P < 0.05, Student’s
t test. CRD cysteine-rich domain, CTD cytoplasmic tail domain, DI disintegrin, ELD epidermal growth factor-like domain, MP metalloproteinase, PRO
prodomain, and TD transmembrane domain.
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Subsequently, 3.5 μl C. elegans miR-39 (Qiagen, 219610)
(160 nM) was added as a spike in each sample to control
for miRNA recovery. RNA was then isolated as per
protocol. Reverse transcription was carried out using the
TaqMan MicroRNA Reverse Transcription Kit (Invitro-
gen, 4366596). miRNA expression was assessed by
qPCR, and values were calibrated to the control C. ele-
gans miR-39 (Cel-miR-39-3p). Single tube TaqMan as-
says (Invitrogen, 4427975) for hsa-miR-720 were carried
out as follows: 95 °C for 10 min, then 40 cycles of 95 °C
for 15 s and 60 °C for 60 s. All analyses were performed
in triplicate and the data were normalized to hsa-miR-16
(Invitrogen, 4427975). Serum levels of miR-720 in pa-
tients versus healthy individuals are presented as average
fold-change ± SD.
Results
ADAM8 regulates miRNA expression in MDA-MB-231
TNBC cells
ADAM8 is synthesized as a multidomain proteolytically
inactive proform protein (120-kDa), which can autocata-
lytically clip its prodomain, leaving an active 90-kDa
protein with MP activity, which can be further processed
to a 60-kDa remnant transmembrane form lacking the
MP domain but retaining the disintegrin domain and C-
terminal region (Fig. 1a). As ADAM8 promotes the mi-
gratory and invasive phenotype of TNBC cells [24], we
sought to determine whether any of these effects were
mediated via downstream miRNAs. Firstly, we asked
whether ADAM8 regulates miRNA expression in MDA-
MB-231 TNBC cells using an RT-qPCR-based miRNA
array. Seventy-two hours following transfection of
MDA-MB-231 cells with either siADAM8-1 or siA-
DAM8-2 or a control siRNA (siCtrl), WCEs were iso-
lated and subjected to Western blotting (Fig. 1b). Both
ADAM8 siRNAs effectively reduced the levels of
ADAM8 compared to the siCtrl. As siADAM8-2 was
previously shown to be slightly more effective in down-
regulating ADAM8 function in MDA-MB-231 cells [24],
it was selected to knockdown ADAM8 for the miRNA
array assay. RNA was isolated from two independent
cultures of MDA-MB-231 cells 72 h post-transfection
with siADAM8-2. The RNA preparations were subjected
to TaqMan low-density miRNA array card analysis. The
relative miRNA expression in the siADAM8 RNA prepa-
rations compared to the siCtrl RNA was calculated using
the SDS software. A threshold increase or decrease of
twofold was used as the cut-off, and 68 miRNAs were
differentially regulated greater than or equal to twofold
upon ADAM8 knockdown with siADAM8-2 (Fig. 1c). Of
these 68 miRNAs, 66 miRNAs were downregulated and
2 miRNAs were upregulated. Literature analysis was per-
formed to identify the miRNAs in this subset that had
been reported aberrantly expressed in cancer [33–42],
and 11 oncogenic miRNAs (oncomiRs) were identified.
To confirm that these miRNAs were indeed regulated by
ADAM8, RT-qPCR for these 11 miRNAs was performed
using three independently isolated RNA preparations
from MDA-MB-231 cells treated with siADAM8-1 or
siADAM8-2 versus siCtrl. As seen in Fig. 1d, knockdown
of ADAM8 with siADAM8-2 led to reduced levels of all
11 RNAs, confirming the TaqMan low-density miRNA
array card analysis. However, treatment with siADAM8-
1 led to reduced levels of only eight miRNAs (miR-181a-
2, miR-29c, miR-29c*, miR-98, miR-520c-3p, miR-93,
miR-130b, and miR-720), whereas three miRNAs
showed increased expression, including miR-30d, miR-
20a and miR-106*b (Fig. 1d), suggesting these miRNAs
may not be regulated specifically by ADAM8 or may
have differential regulation via splice variants. Overall,
multiple miRNAs appear to be regulated by ADAM8 or
a downstream mediator/pathway.
Expression of miR-720 is induced by ADAM8
While all of the ADAM8-regulated miRNAs have been
implicated in various aspects of tumorigenesis, we were
particularly interested in miR-720 since it has been re-
ported to be highly expressed and abundantly released
from breast cancer cells [25, 43–45] and detected in the
blood of patients with multiple myeloma [46]. Also, we
found that miR-720 was highly expressed in MDA-MB-
231 cells (Additional file 2: Figure S1). The transfection
of MDA-MB-231 cells with siADAM8-2 and siADAM8-1
led to a 3.7-fold and 1.7-fold downregulation of miR-
720, respectively (Fig. 1d). Recently, Lerebours et al. [25]
identified miR-720 in a set of five miRNAs as a predict-
ive marker of poor prognosis in patients with inflamma-
tory breast cancer (IBC), which we have found also
frequently express ADAM8 (data not shown). Thus, we
next analyzed the effects of ADAM8 knockdown on
SUM-149 cells, a triple-negative IBC line which has been
characterized as a basal-like 2 (BL2) subtype line of
TNBC [47] that expresses high levels of ADAM8 [24].
SUM-149 cells were transfected with siCtrl, siADAM8-1
or siADAM8-2, and after 72 h WCEs and RNA were iso-
lated. Western blot analysis confirmed the effective
knockdown of ADAM8 by the two specific siRNAs
(Fig. 1e). RT-qPCR of RNA isolated in three independent
experiments indicated miR-720 levels were reduced by
2-fold and 1.7-fold, respectively, in SUM-149 cells
treated with siADAM8-2 and siADAM8-1 compared to
the siCtrl (Fig. 1f ). Thus, knockdown of ADAM8 de-
creases miR-720 levels in both MDA-MB-231 and SUM-
149 TNBC cells.
We next sought to confirm that miR-720 is secreted
from breast cancer cells, as reported previously, and that
its secretion is regulated by ADAM8. To address this
question, we isolated exosomes released into the media
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by MDA-MB-231 and SUM-149 TNBC cells, extracted
miRNA and subjected the RNA to RT-qPCR for miR-
720. Consistent with the findings of Pigati et al. [45],
these two breast cancer cells lines were shown to release
miR-720 (Fig. 2a). To confirm that miR-720 release is
controlled by ADAM8, exosomal levels of miR-720 in
cultures of MDA-MB-231 cells with shCtrl RNA
(shCtrl-3) versus shA8-20 with stable shRNA knock-
down of ADAM8 [24] were compared. The release of
miR-720 into the exosomes by shA8-20 cells was de-
creased relative to the shCtrl-3 cells (Fig. 2b). Thus,
TNBC cells release miR-720 in an ADAM8-dependent
manner.
To further assess the role of ADAM8 in regulation of
miR-720, we ectopically expressed full-length ADAM8
in cell lines that either express low levels of ADAM8 or
are ADAM8-negative. In particular, MDA-MB-231 cells
with stable ADAM8 shRNA knockdown (shA8-20) and
HEK-293 that do not express ADAM8 [24] were
selected. WCEs and RNA were isolated 48 h after trans-
fection with an ADAM8 expression vector or with
empty vector (EV) DNA as control. Western blotting
confirmed the ectopic expression and processing of
ADAM8 in these cells (Fig. 2c, d). As judged by RT-
qPCR, ADAM8 expression led to an increase in miR-
720 level of 1.4-fold in shA8-20 cells (Fig. 2e) and of
threefold in HEK-293 cells (Fig. 2f ). This was consistent
with the relative levels of ectopic ADAM8 overexpres-
sion and transfection efficiencies of these lines. Previ-
ously, we showed that culturing Hs578T TNBC cells in
suspension (3D condition) increased the levels and pro-
cessing of ADAM8 compared to growth on plastic (two-
dimensional (2D) condition) [24]. Thus, we asked
whether this increase in endogenous ADAM8 expression
affects miR-720 levels. As seen previously, significant in-
creases in ADAM8 levels were detected when Hs578T
cells were grown in suspension compared to those
grown on plastic (Fig. 2g). RT-qPCR analysis of RNA
Fig. 2 miR-720 is secreted in media and its expression is positively regulated by ADAM8 in TNBC and HEK-293 cells. a Cultures of MDA-MB-231
and SUM-149 cells at 50–70 % confluency were grown either in serum-free or exosome-depleted FBS media, respectively. After 72 h, supernatants
were collected, exosomes purified, and RNA isolated and subjected to RT-qPCR analysis for miR-720. miRNA expression levels are given as
mean ± SEM from two independent experiments. b Exosomes were purified from control shRNA (shCtrl-3) and a stable clone of MDA-MB-231
cells expressing ADAM8 shRNA (shA8-20) and relative miR-720 expression levels determined, as described for MDA-MB-231 cells in part (a). miR-720
levels in exosomes released by the two lines are given as the mean ± SEM from two independent experiments. c–f MDA-MB-231 shA8-20 and
HEK-293 cells were transfected in six-well plates with 4 or 2 μg, respectively, of empty vector (EV) or an ADAM8 expression vector (A8) for 48 h. WCEs
from shA8-20 (c) and HEK-293 (d) cells were subjected to Western blotting for ADAM8 and β-actin, as above. Representative blots are shown (n = 3).
RNAs from shA8-20 (e) and HEK-293 (f) cells were subjected to RT-qPCR for miR-720 levels, as in Fig. 1 f. Control condition (EV) is set to 1 (mean ± SD
from three independent experiments). g, h Hs578T cells were cultured on plastic (two-dimensional (2D)) or in suspension (three-dimensional (3D)) for
48 h, and WCEs and RNA isolated. WCEs were analyzed by Western blotting for ADAM8 and β-actin (g), and RNA subjected to RT-qPCR for miR-720
levels as above (h). EV is set to 1 (mean ± SD from three independent experiments). *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test
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collected from cells after 48 h of culture revealed that
miR-720 levels were elevated more than threefold in
Hs578T cells in 3D versus 2D cultures (Fig. 2h). Thus,
endogenous or ectopic expression of ADAM8 leads to
increased miR-720 levels.
The MP domain of ADAM8 is not essential to induce
miR-720 expression
To determine how ADAM8 regulates miR-720 expres-
sion, we first tested the role of its MP domain using vec-
tors that express either an ADAM8 protein that is
catalytically inactive or lacking the MP domain. Previ-
ously, it has been reported that a Glu (E330) to Gln
(Q330) mutation (EQ mutation) in the catalytic MP do-
main of mouse ADAM8 led to a proteolytically inactive
protein [22]. We demonstrated that human ADAM8
with analogous EQ mutation was similarly inactive, as
judged by its inability to shed a 29-kDa CD23 fragment
following co-transfection into HEK-293 cells [28]. Here,
HEK-293 cells were transfected with vectors expressing
either WT ADAM8 (WT-3.1) or EQ ADAM8 (EQ-3.1)
or empty pcDNA3.1 myc/his EV-3.1 vector DNA as con-
trol. Western blot analysis confirmed the expression of
WT and EQ mutant ADAM8 protein (Fig. 3a). As found
previously [28], a band was seen with EQ-3.1 that ran
somewhat faster than the 90-kDa active ADAM8 seen
Fig. 3 ADAM8 DI domain induces expression of miR-720 via β1-integrin signaling. a, b HEK-293 cells were transfected in six-well plates with 2 μg
of either pcDNA3.1 myc-his vector (EV-3.1), or vectors expressing ADAM8 (WT-3.1 or EQ-3.1) for 48 h. WCEs and RNA were then collected. Samples
of WCEs were subjected to Western blotting for ADAM8 and β-actin, as in Fig. 1. A representative blot is shown (n = 3) (a). RNAs were subjected
to RT-qPCR for measurement of miR-720 levels and values presented relative to the control condition (EV-3.1), which is set to 1 (mean ± SD from
three independent experiments), as above (b). c, d HEK-293 cells were transfected as above with EV DNA or with vectors expressing ADAM8 WT
or remnant form (Rem.) for 24 h and 48 h. WCEs harvested 48 h after transfection were analyzed for ADAM8 and β-tubulin. A representative blot
is shown (n = 3) (c). RNA was subjected to RT-qPCR for measurement of miR-720 levels. EV control condition is set to 1 (mean ± SD from three
independent experiments) (d). e HEK-293 cells were transfected in 12-well plates with a vector expressing the ADAM8 remnant form (Rem.). After
24 h, the transfected cells were treated with 20 μg/ml ADAM8 antibody MAB10311, which targets the CRD/ELD domains and inhibits DI activity
[24], or isotype-matched control IgG1 for another 24 h. RNA was extracted and subjected to RT-qPCR analysis for miR-720 levels. Control condition
(EV + IgG1) is set to 1 (mean ± SD from three independent experiments). f MDA-MB-231 cells were treated with 10 or 20 μg/ml β1-integrin
(Anti-β1-integ.) antagonist antibody or isotype-matched control IgG2A for 24 h, and miR-720 levels determined by RT-qPCR analysis. Control
condition (IgG2A) is set to 1 (mean ± SD from three independent experiments). **P < 0.01, ***P < 0.001, Student’s t test. Not sig. not significant,
Rel. relative
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with the WT-3.1 vector, presumably resulting from non-
autocatalytic proteolysis of the EQ mutant proform. An
essentially equal increase in miR-720 levels was triggered
by the WT-3.1 and EQ-3.1 ADAM8 proteins (Fig. 3b),
suggesting that the activity of the MP domain of
ADAM8 is not required for miR-720 induction. To con-
firm that the metalloproteinase activity was not essential,
we tested the ability of the ADAM8 remnant form,
which lacks the MP domain, to induce miR-720. HEK-
293 cells were transfected with pcDNA3 vectors express-
ing either WT ADAM8 or its remnant form, or control
EV pcDNA3 DNA for 24 or 48 h. Western blot analysis
confirmed substantial expression of the remnant form
(Fig. 3c). At 24 h, the vectors expressing either the WT
or remnant forms of ADAM8 induced the expression of
miR-720 equally (approximately threefold each) com-
pared to the EV control condition (Fig. 3d). At 48 h, a
further increase in miR-720 levels was observed with
both forms, but was more pronounced with the WT
likely due to expression of both active and remnant
ADAM8 (Fig. 3d). Thus, the remnant form of ADAM8,
which lacks metalloproteinase activity, effectively in-
duces miR-720 expression, suggesting the MP domain of
ADAM8 is not involved in the induction.
miR-720 induction is mediated by the DI/CRD/ELD region
of ADAM8 via activation of a β1-integrin/ERK cascade
The MP and DI domains have been shown to constitute
two independent functional cores of ADAM8 activity
[18]. The DI domain and the CRD/ELD portions of
ADAM proteins have been suggested to form an essen-
tial binding domain [48] for interaction with integrins
[49, 50]. Since we have shown that ADAM8 is required
for β1-integrin activation [24], which is known to par-
ticipate in adhesion of breast cancer cells to the endo-
thelium [51, 52], we investigated the potential role of the
DI/CRD/ELD domains in miR-720 activation. The ef-
fects of treatment with the MAB10311 monoclonal anti-
body that specifically recognizes the CRD/ELD region of
ADAM8 on miR-720 expression were tested. HEK-293
cells ectopically expressing the remnant form of
ADAM8 or EV DNA were incubated with 20 μg/ml of
either ADAM8 antibody MAB10311 or isotype-matched
control IgG1 (MAB002). After 24 h of treatment, RNA
was extracted and RT-qPCR analysis performed to meas-
ure miR-720 levels (Fig. 3e). The induction of miR-720
by the remnant form was significantly inhibited (~40 %
inhibition) upon addition of the anti-ADAM8 CRD/ELD
antibody. To determine whether direct inhibition of β1-
integrin signaling was sufficient to reduce the levels of
miR-720 expression, MDA-MB-231 cells were treated
for 24 h with 10 or 20 μg/ml of an antagonist anti-
human β1-integrin antibody or with an isotype-matched
IgG2A. The levels of miR-720 were significantly
decreased by approximately 10-fold upon treatment with
the β1-integrin antibody when compared to the control
(Fig. 3f ). Altogether, these findings indicate that the DI/
CRD/ELD domains of ADAM8 play a key role in the
regulation of miR-720 via activation of the β1-integrin
signaling pathway.
Overexpression of ADAM8 has been shown to also ac-
tivate ERK/MAPK signaling in osteoclasts [53]. To de-
termine whether ADAM8 leads to ERK activation in
breast cancer cells, we tested ERK1/2 phosphorylation
(p44/p42) levels in Hs578T cells that overexpress
ADAM8 naturally when cultured under 3D conditions
versus 2D, as shown above in Fig. 2g. WCEs from
Hs578T cells cultured in 2D versus 3D were subjected to
Western blotting. In cells grown under 3D conditions,
where cells display elevated expression and processing of
ADAM8 (Fig. 2g), we observed a 2.7-fold increase in the
levels of pERK1/2 (Fig. 4a). A similar increase in levels
of pERK1/2 was observed in HEK cells transfected with
either WT or the remnant form of ADAM8 (Fig. 4b), in-
dicating that the MP domain is not required for activa-
tion of ERK signaling, consistent with the induction of
miR-720 observed above. Interestingly, β1-integrin has
also been shown to signal predominantly through the re-
cruitment and activation of Src-family kinases, which
then activate a downstream cascade including ERK/
MAPK and JNK kinases [54]. As phosphorylation of
ERK has been implicated in the induction of both cell
migration and anchorage-independent growth in breast
cancer [55], we asked whether ERK signaling was in-
volved in miR-720 regulation. To address this question,
MDA-MB-231 cells were treated with either 25 μM of
the ERK specific inhibitor FR180204 [56], or an equiva-
lent volume of DMSO. After 24 h, WCEs and RNA were
isolated. As expected, treatment with FR180204 caused a
twofold decrease in pERK1/2 levels in comparison to
DMSO (Fig. 4c). Notably, a significant decrease in miR-
720 expression was observed upon ERK inhibition
(Fig. 4d). Similarly, treatment of SUM-149 cells with
FR180204 caused a 40 % drop in miR-720 expression
(Fig. 4e). Thus, the induction of miR-720 by ADAM8 is
mediated via activation of a β1-integrin to ERK1/2 sig-
naling pathway in TNBC cells.
miR-720 mediates ADAM8-induced aggressive phenotype
in TNBC cells
As ADAM8 promotes the migratory and invasive pheno-
type of TNBC cells [24], the role of miR-720 as a medi-
ator of these aggressive properties was tested using a
specific anti-miR. MDA-MB-231 cells were transfected
with 50 nM anti-miR-720 for 48 h and a 70 % decrease
in miR-720 levels was measured (Fig. 5a), leading to a
40 % decrease in MDA-MB-231 cell migration in a
Boyden chamber assay (Fig. 5b). Furthermore, miR-720
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knockdown robustly inhibited the capacity of MDA-MB-
231 cells to form characteristic branching colonies in
Matrigel (Fig. 5c, left panel). The numbers of branched
colonies were counted and a ~60 % reduction was seen
in three independent experiments (Fig. 5c, right panel).
To determine whether miR-720 was likely playing a role
in β1-integrin-mediated transmigration of cancer cells
through the endothelial layer of blood vessel walls [57],
the effects of miR-720 knockdown on transendothelial
migration were monitored. MDA-MB-231 cells that had
been treated with 50 nM anti-miR-720 for 48 h were
plated over a HUVEC monolayer in a Boyden chamber
and the number of cells that migrated through the endo-
thelial barrier measured after 24 h. The capacity of
MDA-MB-231 cells to transmigrate through the endo-
thelial cell layer was reduced by 60 % after miR-720
knockdown (Fig. 5d). In contrast, knockdown of miR-
720 over a 24-h period did not decrease 2D growth of
MDA-MB-231 cells (Fig. 5e), consistent with our previ-
ous findings that growth of TNBC cells on plastic was
Fig. 4 ADAM8 promotes ERK activation, which is required for miR-720 expression. a Hs578T cells were cultured on plastic (two-dimensional (2D)) or in
suspension (three-dimensional (3D)) for 48 h. WCEs and RNA were then isolated. WCEs were subjected to Western blotting for the ERK1/2 phosphorylated
form (pERK1/2) and β-actin. The data from this and two other replicate experiments were quantified. The value of pERK1/2 in the 3D culture is given relative
to the 2D culture, which was set to 1.0. b HEK-293 cells were transfected as above with empty vector (EV) or with vectors expressing ADAM8 (WT) or
remnant form (Rem.) for 48 h. WCEs were analyzed for pERK1/2 and β-tubulin. The data from this and two independent replicate experiments were
quantified. The value of pERK1/2 in the control EV DNA was set to 1.0. c, d MDA-MB-231 cells were cultured in serum-free medium for 24 h, and treated
with 25 μM of ERK inhibitor FR180204 or control carrier DMSO for an additional 24 h. WCEs and RNA were collected. WCEs were subjected to Western
blotting for pERK1/2 and β-tubulin (c). The data from this and two independent replicate experiments were quantified. The value of pERK1/2 in the DMSO
sample was set to 1.0. RNA was subjected to RT-qPCR analysis and miR-720 levels were determined. The control condition (DMSO) was set to
1.0 (mean ± SD from three independent experiments) (d). e SUM-149 cells were cultured in serum-free medium for 24 h, treated with 25 μM of
ERK inhibitor FR180204 or carrier DMSO as a control for an additional 24 h. RNA was subjected to RT-qPCR analysis for miR-720 levels. The DMSO
control condition was set to 1.0 (mean ± SD from three independent experiments). **P < 0.01, ***P < 0.001, Student’s t test
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unaffected by knockdown of ADAM8 [24]. To extend
these observations to a second TNBC line, the roles of
miR-720 in SUM-149 cells were evaluated. Knockdown
of miR-720 (Fig. 6a) resulted in a 40 % decrease in the
ability of SUM-149 cells to migrate (Fig. 6b) and to in-
vade through Matrigel (Fig. 6c), while 2D growth was
not affected (Fig. 6d).
Finally, to test whether addition of miR-720 was sufficient
to overcome the loss of the aggressive phenotype of TNBC
cells upon ADAM8 depletion, cultures of shA8-20 MDA-
MB-231 cells stably expressing an ADAM8 shRNA were
transfected with 200 pmol of a miR-720 mimic or control
miRNA. Expression of the miR-720 mimic resulted in a 10-
fold increase in miR-720 levels compared to the control
(Fig. 7a). Notably, miR-720 expression was sufficient to pro-
foundly increase the formation of branched colonies from
shA8-20 MDA-MB-231 cells in a Matrigel 3D-outgrowth
assay (Fig. 7b), and led to more than a 50 % increase in
their ability to migrate (Fig. 7c). As expected, growth of the
shA8-20 cells on plastic was unaffected by expression of
the miR-720 mimic (Fig. 7d). Thus, the ADAM8 down-
stream target miR-720 participates in many aspects of the
invasive and migratory properties of TNBC cells, suggesting
that miR-720 is an important mediator of the aggressive
properties of TNBC cells induced by ADAM8.
miR-720 is detected in the plasma of mice bearing
ADAM8-positive TNBC tumors
To begin to evaluate the potential of using miR-720
as a biomarker for ADAM8-expressing TNBCs, an
Fig. 5 miR-720 maintains the migratory and invasive properties of
MDA-MB-231 cells. MDA-MB-231 cells were transfected with 50 nM
anti-miR-720 or anti-miR-negative control (Ctrl) for 48 h. Either RNA was
isolated (a) or transfected cells subjected to functional assays (b–e). a
miR-720 levels. RNA was subjected to RT-qPCR for miR-720. Control
condition (Ctrl) was set to 1.0 (mean ± SD from three independent
experiments). b Migration assay. Transfected cells were subjected to a
migration assay in a Boyden chamber over a 24-h period. The cells that
migrated through the chamber were quantified using crystal violet
staining. Ctrl was set to 100 % (mean ± SD from three independent
experiments). c Matrigel assay. Transfected cells were grown in Matrigel
for 11–15 days and then photographed using a Nikon eclipse TS100
microscope at 10× magnification. Scale bar= 100 μm. Representative
images of two independent experiments with similar results are shown
(left panels). The number of branched colonies were counted. The count
in the control sample was set to 1.0 (right panel). d Transendothelial
migration assay. Transfected MDA-MB-231 cells were plated in a Boyden
chamber that had been coated with a confluent monolayer of HUVEC
cells, and the cancer cells that invaded through the HUVEC layer over a
24-h period were quantified using crystal violet staining. Ctrl value for
transendothelial (transendo.) migration was set to 100 % (mean ± SD
from three independent experiments) and relative (Rel.) migration values
given. e ATP assay. Transfected cells were grown for 24 h and ATP levels
were measured using an ATPlite 1Step assay. Ctrl was set to 100 %
(mean ± SD from three independent experiments). *P< 0.05, ***P< 0.001,
Student’s t test. Not sig. not significant
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orthotopic mouse model was performed using control
MDA-MB-231 cells (shCtrl-3 clone), which express high
levels of ADAM8 and miR-720. In our preliminary ana-
lysis, the plasma levels of miR-720 appeared to vary be-
tween individual mice (data not shown). Thus, plasma
was collected from each 6-week-old female NOD/SCID
mouse (n = 5) a day before TNBC cell inoculation into the
mammary fat pad, and used to establish baseline miR-720
levels for each individual mouse. On day 1, 2.5 × 106
shCtrl-3 MDA-MB-231 cells were implanted into the
fourth inguinal mammary fat pad and primary tumor
growth was monitored by palpation and caliper measure-
ment twice a week thereafter (Fig. 8a). Little growth of the
tumors was detected within the first 7–9 days, as reported
previously [24]. Plasma was collected 7 days after cell
implantation when the tumors were barely palpable.
Tumor growth was followed for a total of 21 days (Fig. 8a).
A significant increase in miR-720 levels of about 40-fold
was detected in the blood of mice at the 7-day time point
(Fig. 8b) and remained elevated above 10-fold to day 21
(data not shown). It was interesting to note that the mice
with the two fastest growing tumors (mouse 1 and mouse
2) had the highest miR-720 levels at day 7. Thus, substan-
tial increases in miR-720 levels can be detected early, prior
to the increase in tumor growth when tumor sizes are
fairly small.
Fig. 6 miR-720 maintains the migratory and invasive properties of
SUM-149 cells. SUM-149 cells were transfected with 50 nM anti-miR-720
or anti-miR-negative control (Ctrl) for 48 h, and either RNA isolated or
cells subjected to functional assays. a miR-720 levels were determined
using RT-qPCR, as in Fig. 5a. b Migration assay. Transfected cells that
migrated through a Boyden chamber over a 24-h period were quantified
as in Fig. 5b. Ctrl was set to 100 % (mean ± SD from three independent
experiments). c Invasion assay. Transfected cells that invaded through a
Matrigel-coated Boyden chamber in a 12-h period were quantified.
Ctrl was set to 100 % (mean ± SD from three independent experiments).
d ATP assay. Transfected cells were grown for 24 h and ATP levels
measured using an ATPlite 1Step assay. Ctrl was set to 100 %
(mean± SD from three independent experiments). **P< 0.01, ***P< 0.001,
Student’s t test. Not sig. not significant, Rel. relative
Fig. 7 Ectopic expression of miR-720 restores the migratory and
invasive abilities of MDA-MB-231 cells with stable knockdown of
ADAM8. MDA-MB-231 shA8-20 clonal cells, with stable ADAM8
knockdown, were transfected in six-well plates with 200 pmol of
control mimic (Ctrl) or miR-720 mimic. After 48 h, either RNAs were
isolated or cells subjected to functional assays. a miR-720 levels were
determined by RT-qPCR. The control mimic (Ctrl) was set to 1 (mean ±
SD from three independent experiments). b Transfected MDA-MB-231
shA8-20 cells were plated in Matrigel and photographed at 10×
magnification after 11–15 days of culture. Representative images of
two independent experiments with similar results are shown.
Scale bar = 100 μm. c Transfected cells were subjected to a Boyden
chamber migration assay for 24 h, as in Fig. 5. Ctrl was set to 100 %
(mean ± SD from three independent experiments). d Transfected
cells were subjected to an ATP assay following growth on plastic
for 24 h. Ctrl was set to 100 % (mean ± SD from three independent
experiments). **P < 0.01, ***P < 0.001, Student’s t test. Not sig. not
significant, Rel. relative
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miR-720 levels are elevated in serum of TNBC patients
with high ADAM8 levels
The MP domain alone or the entire ectodomain of
ADAM8 has been shown to be secreted from cells ex-
pressing ADAM8 [22]. This soluble fraction of ADAM8
was recently found to be shed from malignant breast tu-
mors into the blood of patients [24]. Given that miR-720
levels were significantly higher in the blood of mice
bearing ADAM8-positive TNBC tumors, we next asked
whether miR-720 levels are elevated in the serum of
TNBC patients with detectable ADAM8 in the blood
versus normal individuals. Serum samples were obtained
from consenting TNBC patients taken at the time of
diagnosis, before any treatment was provided, and from
normal healthy individuals. Samples were first analyzed
for levels of soluble ADAM8 protein shed into the blood
using an ELISA kit (R&D Systems). ADAM8 levels were
significantly higher in serum samples of TNBC patients
in comparison to normal healthy individuals (Fig. 9a).
Interestingly, 78 % (29/37) of the TNBC patients had
ADAM8 levels above the median value observed in
healthy individuals, whereas levels of eight TNBC pa-
tient serum samples were below the medium value
(Fig. 9b). Next, RNA was extracted from the serum sam-
ples using a Macherey-Nagel Nucleospin miRNA plasma
kit and subjected to RT-PCR for miR-720. Unfortunately,
RNA yield and quality from three of the samples were
poor as judged by RNA integrity analysis using an Agi-
lent bioanalyzer, and these samples had to be excluded
from the analysis. hsa-miR-16 was used to normalize the
data as its levels remained unchanged in normal versus
patient samples (Additional file 3: Figure S2), similar to
previous reports by others in healthy individuals versus
breast cancer patients [58]. As seen in Fig. 9c, levels of
miR-720 were significantly higher in patient samples
with elevated amounts of ADAM8, whereas normal
healthy individuals and TNBC patients with comparably
low ADAM8 levels displayed low levels of miR-720. This
increase was not correlated with tumor size (Additional
file 3: Figure S2). Thus, higher levels of miR-720 are
found in the serum of TNBC patients with high ADAM8
serum levels.
Discussion
We show for the first time that ADAM8 signaling regu-
lates a miRNA subset and that miR-720 specifically plays
a critical role in the ability of this transmembrane pro-
tein to promote an aggressive phenotype in TNBC cells.
In MDA-MB-231 and SUM-149 TNBC cells in culture,
knockdown of ADAM8 led to decreased levels of miR-
720 while ADAM8 ectopic overexpression increased
miR-720 expression. Surprisingly, the induction of miR-
720 did not require the metalloproteinase activity of
ADAM8, as ectopic expression of either an ADAM8
mutant with a catalytically inactive MP domain or the
remnant form lacking the MP domain was essentially as
effective as full-length ADAM8 in promoting miR-720
expression. An antibody against the CRD/ELD domain
that inhibits the DI activity of ADAM8 [24] or an antag-
onist antibody against β1-integrin significantly reduced
miR-720 levels, mapping the activity to the DI/CRD/
ELD domains of ADAM8. The addition of an ERK-
specific inhibitor significantly decreased the levels of
miR-720. Together, these findings implicate activation of
Fig. 8 miR-720 is detected in the plasma of mice before tumors
become palpable. MDA-MB-231 shCtrl-3 cells (2.5 × 106 in 40 μl 50 %
Matrigel) were implanted on day 1 into the mammary fat pad of
female mice (n = 5). Tumor volume was measured on the indicated
days. Blood was collected on the day prior to implantation and on
day 7 by submandibular bleeding and centrifuged to obtain clear
plasma. Total RNA was collected from plasma samples and miR-720
levels were determined using RT-qPCR. a Tumor growth in individual
mice from day 1 to day 21. Tumor volume (cm3) is presented. b
Relative miR-720 levels in plasma of the individual mice at day 0 and
day 7. **P < 0.005, Student’s t test
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β1-integrin signaling by the DI/CRD/ELD region of
ADAM8, and downstream activation of the ERK path-
way in miR-720 induction. Significantly, knockdown of
miR-720 using an antagomiR decreased the migratory
and invasive phenotype of TNBC cells, whereas ectopic
miR-720 expression restored these properties. We con-
firmed that miR-720 is secreted from TNBC cells, con-
sistent with observations made in other breast cancer
lines [45], and increased miR-720 levels were detected in
the blood of mice 7 days following orthotopic implant-
ation of ADAM8-positive TNBC cells, when tumors
were barely palpable. Higher levels of miR-720 were de-
tected in the blood of TNBC patients with elevated
amounts of circulating ADAM8. Thus, miR-720 is an es-
sential mediator of ADAM8 in the promotion of the ag-
gressive phenotype of TNBC cells, and as a secreted
factor has the potential to function as a biomarker for
early detection of ADAM8-positive recurrent TNBCs.
While miRNAs have been shown to play a vital role in
breast cancer development and to regulate the functions
of a number of critical genes [33, 59, 60], very little is
known about the stimuli and processes regulating the
biogenesis of miRNAs themselves. Butz et al. [61] and
Wang et al. [62] elucidated complex pathways down-
stream of TGF-β1 and c-MYC signaling, respectively,
that modulated miRNA processing. For miR-720, work
by Ragusa et al. [63] suggested that its expression may
be induced downstream of a MAPK/ERK pathway in
colorectal cancer cells, although the mechanism of acti-
vation was not elucidated. Our results agree with and
extend these findings, showing for the first time that
ADAM8 initiates the induction of miR-720 via activation
of the β1-integrin/ERK signaling cascade to promote mi-
gration and invasion in breast cancer cells. These find-
ings shed light into the complex mechanism by which
ADAM8 promotes aggressive phenotype of TNBCs.
Many studies have implicated miR-720 in transformed
phenotype or suggested its use in cancer diagnosis or as
a prognostic marker for cancer [46, 64, 65]. As discussed
above, Lerebours et al. [25] identified miR-720 in a set
Fig. 9 High levels of miR-720 are detected in the serum of
triple-negative breast cancer (TNBC) patients with higher
ADAM8 levels. Sera were obtained from 37 TNBC patients and
15 healthy individuals and analyzed for protein levels of
ADAM8 and RNA levels of miR-720. a, b ADAM8 protein levels
were measured by ELISA in serum samples from TNBC patients
and healthy individuals (a). TNBC patients were separated
based on their ADAM8 levels: high ADAM8 > 100 pg/ml and
low ADAM8 < 100 pg/ml (b). c Total RNA was collected from
serum samples and miR-720 levels were determined using
RT-qPCR. Relative miR-720 levels in serum of TNBC patients
with high ADAM8, low ADAM8 and normal individuals are
presented. *P <0.05, ***P < 0.001, ****P < 0.0001, Welch’s t test.
NS not significant
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of five miRNAs that can serve as predictive markers of
poor prognosis in patients with IBC, which we have
found also frequently express ADAM8 (data not shown).
Similarly, Park and coworkers reported upregulation of
miR-720 in blood of patients with metastatic ER+/HER2-
breast cancer [66]. Consistently, miR-720 is upregulated in
a variety of other tumors including colorectal and bladder
cancers, malignant melanoma, renal cell carcinoma and
multiple myeloma [46, 63, 65, 67–71]. In contrast, Li et al.
[72] reported that miR-720 prevented a more aggressive
phenotype of breast cancer cells, specifically via repression
of synthesis of the EMT marker TWIST1 in MDA-MB-
231 breast cancer cells. While potentially interesting,
the expression levels of TWIST1, miR-720, and N-
cadherin in the stock of MDA-MB-231 cells used in this
study are inconsistent with NIH criteria established for
this line, as judged by analysis of the NCI-60 cell line
panel [73, 74].
In addition to miR-720, many of the 68 miRNAs mod-
ulated by ADAM8 have been found to be upregulated in
breast cancer or previously implicated in tumorigenesis
(such as miR-19a, miR-106b, miR-181a-2, miR-30a, miR-
93, miR-30d, and miR-10b) [37, 40, 75–78]. Out of these
68 miRNAs, two (miR-324 and miR-7) were found to be
downregulated by ADAM8. Interestingly, miR-7 is a po-
tent tumor suppressor in breast cancer cells [79] consist-
ent with the observed ability of ADAM8 to repress its
expression. Altogether, these data suggest that ADAM8,
through β1-integrin and ERK activation, may regulate a
large network of oncomiRs, which likely plays additional
roles in promoting invasion and metastasis of TNBC tu-
mors expressing high ADAM8 levels.
Stability of miRNAs in both primary tumors and in
the blood (plasma and serum samples) makes them at-
tractive potential biomarkers for non-invasive monitor-
ing of cancer recurrence and for evaluating treatment
efficacy. Recent studies have shown the importance of
miRNAs as biomarkers in breast cancer [80–87]. In par-
ticular, the level of miR-210 was found to be a good indi-
cator of the sensitivity of breast cancer patients to
trastuzumab [80]. We have shown that levels of miR-720
are increased in the blood of mice bearing barely palp-
able ADAM8-positive tumors. Furthermore, elevated
levels of miR-720 were seen in the serum of TNBC pa-
tients with high amounts of soluble ADAM8 protein. Al-
though the miR-720 levels in serum of TNBC patients
versus healthy individuals were statistically significant,
they were not as elevated as the ADAM8 protein. This
finding suggests that miR-720 needs to be used along
with other tumor markers for detection of disease, and
that miR-720 might be a better marker for recurrence
where its levels in the serum under a disease-free state
for a patient can be established. Notably, other miRNAs
found modulated by ADAM8 in this study have been
recently reported to help predict breast cancer risk and
tumor relapse in TNBC patients [88, 89]. For example,
miR-18b, miR-20a, and miR-30d have been reported to
be highly expressed in the serum of relapsing TNBC pa-
tients [88]. Also miR-195 was upregulated in the serum
of breast cancer patients in the study by Mishra et al.
[82], and served within a signature for early detection.
Lastly, a recent endpoint study of patient serum samples
showed that increased miR-720 levels can be detected in
the whole blood of breast cancer patients with meta-
static disease [66], consistent with our data showing high
ADAM8 expression in almost half of all metastases in
breast cancer patients [24]. Taken together with our
data, these findings suggest that miR-720 holds potential
for use as a biomarker along with a group of miRNAs
regulated by ADAM8 and associated with metastasis for
early diagnosis of recurrent TNBC or as a pharmacody-
namic marker for treatment efficacy.
Conclusions
In summary, we have shown that ADAM8 regulates
miR-720 to promote invasion and metastasis of TNBC.
ADAM8 induces miR-720 by activation of the β1-
integrin/ERK signaling cascade using its DI/CRD/ELD
domain, whereas its MP domain is not essential for this
induction. Ectopic miR-720 was sufficient to promote an
invasive and migratory phenotype in TNBC cells lacking
ADAM8, indicating again that miR-720 is a crucial
downstream player of the ADAM8 pathway. Lastly, we
have shown that elevated levels of miR-720 can be de-
tected in the blood of mice with barely palpable tumors,
as well as in the serum of TNBC patients with high
amounts of soluble ADAM8, suggesting that miR-720
has potential as a biomarker for TNBCs.
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